Literature DB >> 18397824

Concentration and microsatellite status of plasma DNA for monitoring patients with renal carcinoma.

Roberto A Perego1, Matteo Corizzato, Paola Brambilla, Stefano Ferrero, Cristina Bianchi, Ester Fasoli, Stefano Signorini, Barbara Torsello, Lara Invernizzi, Silvia Bombelli, Valentina Angeloni, Marina Pitto, Cristina Battaglia, Vanessa Proserpio, Fulvio Magni, Giacomo Galasso, Paolo Mocarelli.   

Abstract

We verified the feasibility of plasma bound method for detecting renal cell carcinoma (RCC) combining the study of plasma DNA concentration and microsatellite alterations (LOH). Plasma DNA concentration was evaluated with real-time PCR in 54 patients with renal neoplasm before surgery and in 20 of these patients during a 26-64 month follow-up. Microsatellite study was performed on tumour tissue DNA of 33 RCC clear cell (RCCcc) and on plasma DNA of 14 RCCcc patients during preoperative and/or follow-up period. Patients had a significantly high (26.4+/-48.3 ng/ml versus controls 3.2+/-1.5 ng/ml; p=0.003) preoperative plasma DNA concentration that decreased after nephrectomy. During follow-up, plasma DNA increased in 12 patients without evidence of neoplasia; 3 patients successively relapsed. Tumour tissue DNA of 25 RCCcc patients (75.8%) displayed microsatellite LOH. Preoperative plasma DNA of 9 patients harboured LOH in 5 cases (55.6%). Augmented plasma DNA of 7 patients displayed LOH in 3 cases (42.9%) at follow-up, and in 1 case preceded the recurrence of disease. Plasma DNA concentration combined with microsatellite LOH in plasma DNA may predict disease recurrence in RCC patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18397824     DOI: 10.1016/j.ejca.2008.03.008

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  7 in total

Review 1.  Role of quantitative and qualitative characteristics of free circulating DNA in the management of patients with non-small cell lung cancer.

Authors:  Paola Ulivi; Rosella Silvestrini
Journal:  Cell Oncol (Dordr)       Date:  2013-11-01       Impact factor: 6.730

Review 2.  Detection of cancer-specific epigenomic changes in biofluids: powerful tools in biomarker discovery and application.

Authors:  André Nogueira da Costa; Zdenko Herceg
Journal:  Mol Oncol       Date:  2012-08-16       Impact factor: 6.603

Review 3.  Stance of MRD in Non-Hodgkin's Lymphoma and its upsurge in the novel era of cell-free DNA.

Authors:  S Garg; A Kumar; R Gupta
Journal:  Clin Transl Oncol       Date:  2021-05-15       Impact factor: 3.405

4.  Renal cell carcinoma primary cultures maintain genomic and phenotypic profile of parental tumor tissues.

Authors:  Ingrid Cifola; Cristina Bianchi; Eleonora Mangano; Silvia Bombelli; Fabio Frascati; Ester Fasoli; Stefano Ferrero; Vitalba Di Stefano; Maria A Zipeto; Fulvio Magni; Stefano Signorini; Cristina Battaglia; Roberto A Perego
Journal:  BMC Cancer       Date:  2011-06-13       Impact factor: 4.430

5.  Circulating tumour markers can define patients with normal colons, benign polyps, and cancers.

Authors:  R Mead; M Duku; P Bhandari; I A Cree
Journal:  Br J Cancer       Date:  2011-06-28       Impact factor: 7.640

6.  Detection of erbB2 copy number variations in plasma of patients with esophageal carcinoma.

Authors:  Immacolata Andolfo; Giuseppe Petrosino; Loredana Vecchione; Pasqualino De Antonellis; Mario Capasso; Donatella Montanaro; Marica Gemei; Giancarlo Troncone; Achille Iolascon; Michele Orditura; Fortunato Ciardiello; Fernando De Vita; Massimo Zollo
Journal:  BMC Cancer       Date:  2011-04-11       Impact factor: 4.430

7.  Diagnostic value of circulating cell-free DNA for renal cell carcinoma: a meta-analysis.

Authors:  Yong Li; Peng Chen; Zhi Chen
Journal:  Transl Cancer Res       Date:  2021-05       Impact factor: 1.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.